{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:21:00Z","timestamp":1761582060521},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A history of prior cancer commonly results in exclusion from cancer clinical trials. However, whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer (APC) remains largely unknown. We therefore aimed to investigate the impact of prior cancer history on these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified patients with advanced prostate cancer diagnosed from 2004 to 2010\u00a0in the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to balance baseline characteristics. Kaplan\u2013Meier method and the Cox proportional hazard model were utilized for survival analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 19,772 eligible APC patients were included, of whom 887 (4.5\u2009%) had a history of prior cancer. Urinary bladder (19\u2009%), colon and cecum (16\u2009%), melanoma of the skin (9\u2009%) malignancies, and non-hodgkin lymphoma (9\u2009%) were the most common types of prior cancer. Patients with a history of prior cancer had slightly inferior overall survival (OS) (AHR\u2009=\u20091.13; 95\u2009% CI [1.02\u20131.26]; P\u2009=\u20090.017) as compared with that of patients without a prior cancer diagnosis. Subgroup analysis further indicated that a history of prior cancer didn\u2019t adversely impact patients\u2019 clinical outcomes, except in patients with a prior cancer diagnosed within 2 years, at advanced stage, or originating from specific sites, including bladder, colon and cecum, or lung and bronchus, or prior chronic lymphocytic leukemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A large proportion of APC patients with a prior cancer history had non-inferior survival to that of patients without a prior cancer diagnosis. These patients may be candidates for relevant cancer trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-021-00792-w","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:34:39Z","timestamp":1613694879000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of prior cancer on survival outcomes for patients with advanced prostate cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Yechen","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duocheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinghu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"issue":"1","key":"792_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"Cancer J Clin"},{"key":"792_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2019.03.002","volume":"76","author":"F Saad","year":"2019","unstructured":"Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA. Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treat Rev. 2019;76:1\u20139.","journal-title":"Cancer Treat Rev"},{"key":"792_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.oraloncology.2019.01.023","volume":"90","author":"YQ Wang","year":"2019","unstructured":"Wang YQ, Lv JW, Tang LL, Du XJ, Chen L, Li WF, Liu X, Guo Y, Lin AH, Mao YP, et al. Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual. Oral Oncol. 2019;90:23\u20139.","journal-title":"Oral Oncol"},{"issue":"5","key":"792_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1740774512456453","volume":"9","author":"M Filion","year":"2012","unstructured":"Filion M, Forget G, Brochu O, Provencher L, Desbiens C, Doyle C, Poirier B, DuRocher M, Camden S, Lemieux J. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment. Clin Trials. 2012;9(5):652\u20139.","journal-title":"Clin Trials"},{"issue":"11","key":"792_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/jnci\/dju302","volume":"106","author":"DE Gerber","year":"2014","unstructured":"Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106(11):302.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"792_CR6","doi-asserted-by":"publisher","first-page":"dvj002","DOI":"10.1093\/jnci\/djv002","volume":"107","author":"AL Laccetti","year":"2015","unstructured":"Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 2015;107(4):dvj002.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"792_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ygyno.2016.12.024","volume":"144","author":"SR Pierce","year":"2017","unstructured":"Pierce SR, Stine JE, Gehrig PA, Havrilesky LJ, Secord AA, Nakayama J, Snavely AC, Moore DT, Kim KH. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. Gynecol Oncol. 2017;144(3):531\u20135.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"792_CR8","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.18632\/aging.102984","volume":"12","author":"F Ji","year":"2020","unstructured":"Ji F, Yang CQ, Li XL, Zhang LL, Yang M, Li JQ, Gao HF, Zhu T, Cheng MY, Li WP, et al. Risk of breast cancer-related death in women with a prior cancer. Aging. 2020;12(7):5894\u2013906.","journal-title":"Aging"},{"issue":"Suppl","key":"792_CR9","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1002\/cncr.29049","volume":"120","author":"KA Cronin","year":"2014","unstructured":"Cronin KA, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014;120(Suppl 23):3755\u20137.","journal-title":"Cancer"},{"issue":"3","key":"792_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"4","key":"792_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","volume":"22","author":"JS de Moor","year":"2013","unstructured":"de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomark Prev. 2013;22(4):561\u201370.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"792_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. Cancer J Clin. 2016;66(4):271\u201389.","journal-title":"Cancer J Clin"},{"issue":"2","key":"792_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4143\/crt.2016.089","volume":"48","author":"CM Oh","year":"2016","unstructured":"Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, Lee DH, Lee KH. Cancer Statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48(2):436\u201350.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"792_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","volume":"10","author":"LB Travis","year":"2013","unstructured":"Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289\u2013301.","journal-title":"Nat Rev Clin Oncol"},{"issue":"30","key":"792_CR15","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","volume":"30","author":"ME Wood","year":"2012","unstructured":"Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734\u201345.","journal-title":"J Clin Oncol"},{"issue":"6","key":"792_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jamaoncol.2017.3605","volume":"4","author":"CC Murphy","year":"2018","unstructured":"Murphy CC, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program. JAMA Oncol. 2018;4(6):832\u20136.","journal-title":"JAMA Oncol"},{"issue":"2","key":"792_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.4143\/crt.2019.210","volume":"52","author":"C Lin","year":"2020","unstructured":"Lin C, Wu J, Ding S, Goh C, Andriani L, Shen K, Zhu L. Impact of prior cancer history on the clinical outcomes in advanced breast cancer: a propensity score-adjusted, population-based study. Cancer Res Treat. 2020;52(2):552\u201362.","journal-title":"Cancer Res Treat"},{"issue":"7","key":"792_CR18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","volume":"25","author":"SM Bluethmann","year":"2016","unstructured":"Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the \u201cSilver Tsunami\u201d: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomark Prev. 2016;25(7):1029\u201336.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"792_CR19","doi-asserted-by":"crossref","unstructured":"Laccetti LA, Pruitt LS, Lei, Xuan AE, Halm ED, Gerber. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.J Natl Cancer Inst 2015.","DOI":"10.1093\/jnci\/djv002"},{"issue":"33","key":"792_CR20","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017;35(33):3737\u201344.","journal-title":"J Clin Oncol"},{"issue":"27","key":"792_CR21","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1200\/JCO.2007.15.3726","volume":"26","author":"J Lemieux","year":"2008","unstructured":"Lemieux J, Goodwin PJ, Pritchard KI, Gelmon KA, Bordeleau LJ, Duchesne T, Camden S, Speers CH. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol. 2008;26(27):4458\u201365.","journal-title":"J Clin Oncol"},{"issue":"4","key":"792_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/cer.15.27","volume":"4","author":"DE Gerber","year":"2015","unstructured":"Gerber DE, Pruitt SL, Halm EA. Should criteria for inclusion in cancer clinical trials be expanded? J Comp Effect Res. 2015;4(4):289\u201391.","journal-title":"J Comp Effect Res"},{"key":"792_CR23","unstructured":"Administration TFaD. Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies. Washington, DC: The Food and Drug Administration c2019 [cited 2019 Mar 7]. https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm."},{"issue":"7","key":"792_CR24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ijc.31543","volume":"143","author":"H Zhou","year":"2018","unstructured":"Zhou H, Huang Y, Qiu Z, Zhao H, Fang W, Yang Y, Zhao Y, Hou X, Ma Y, Hong S, et al. Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: a pan-cancer analysis of the SEER database. Int J Cancer. 2018;143(7):1569\u201377.","journal-title":"Int J Cancer"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-021-00792-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:39:23Z","timestamp":1613695163000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-021-00792-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1186\/s12894-021-00792-w","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All analyses of human data conducted in this study were approved by the Institutional Review Board of The Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was exempted because of the retrospective nature of this study. All authors signed authorization forms and received permission from SEER to access and use the dataset.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}